Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and InflaRx N.V. (NASDAQ:IFRX), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ultragenyx Pharmaceutical Inc.||62||44.06||N/A||-6.34||0.00|
Table 1 highlights Ultragenyx Pharmaceutical Inc. and InflaRx N.V.’s top-line revenue, earnings per share and valuation.
Table 2 has Ultragenyx Pharmaceutical Inc. and InflaRx N.V.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ultragenyx Pharmaceutical Inc.||0.00%||-45.4%||-39.4%|
The Current Ratio of Ultragenyx Pharmaceutical Inc. is 11.8 while its Quick Ratio stands at 11.6. The Current Ratio of rival InflaRx N.V. is 18.1 and its Quick Ratio is has 18.1. InflaRx N.V. is better equipped to clear short and long-term obligations than Ultragenyx Pharmaceutical Inc.
The Ratings and Recommendations for Ultragenyx Pharmaceutical Inc. and InflaRx N.V. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Ultragenyx Pharmaceutical Inc.||0||0||3||3.00|
Ultragenyx Pharmaceutical Inc. has an average target price of $74.33, and a 34.29% upside potential. Competitively InflaRx N.V. has an average target price of $6, with potential upside of 123.05%. The results from earlier shows that analysts opinion suggest that InflaRx N.V. seems more appealing than Ultragenyx Pharmaceutical Inc.
Insider and Institutional Ownership
Institutional investors owned 92.97% of Ultragenyx Pharmaceutical Inc. shares and 53.6% of InflaRx N.V. shares. About 1.6% of Ultragenyx Pharmaceutical Inc.’s share are owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ultragenyx Pharmaceutical Inc.||-1.95%||-4.09%||-6.08%||23.36%||-22.3%||38.59%|
For the past year Ultragenyx Pharmaceutical Inc. has 38.59% stronger performance while InflaRx N.V. has -91.81% weaker performance.
On 5 of the 9 factors InflaRx N.V. beats Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude ChildrenÂ’s Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.